Future Prospects of Global Laboratory Proficiency Testing Market

Dilated cardiomyopathy (DCM) is a disorder in which the heart enlarges and becomes unable to pump blood properly. Other organs, such as the lungs, liver, and kidney, may suffer as a result of the lower heart function. The heart muscles begin to dilate (stretch), resulting in the chamber becoming thinner and larger, and spreading to the right ventricle and atria. Heart muscles do not contract normally as the heart chambers dilate, and they are unable to pump blood normally. In addition, the heart gets weak, which can lead to cardiac failure. Fatigue, edoema in the ankles, legs, and feet, and varicose veins in the neck and belly are all common signs of heart failure.
Rise in congestive heart failure
fuels the growth of dilated cardiomyopathy market
There has
been an increase in the number of people diagnosed with congestive heart
failure, which has resulted in an increase in the number of people diagnosed
with dilated cardiomyopathy. According to the American Heart Association, over
5.7 million persons in the United States suffered from heart failure in 2016.
However, the FDA has not approved any drugs to treat dilated cardiomyopathy. In
addition, firms are investing in the research and development of novel
medications like ARRY-797 and Ixmyelocel-T, which are likely to help the dilated
cardiomyopathy market grow. Increased usage of defibrillators,
pacemakers, and a shortage of appropriate medications are all major
difficulties for the DCM industry.
Developed regions are major growth
engine of dilated cardiomyopathy market
North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa make
up the dilated cardiomyopathy market. Due to an increase in congestive heart
failure cases, the DCM market in North America has seen tremendous expansion.
According to the European Heart Network's 2017 estimate, there are around 3.9
million deaths caused by cardiovascular disease in Europe, with over 1.8
million deaths in the European Union. The Asia Pacific market is the third
largest and is predicted to develop at a faster rate as a result of growing
awareness of cardiovascular disease and need for generic medications, which
will help the DCM market grow.
Key players of dilated cardiomyopathy
market
The DCM
market has a number of participants from all around the world who contribute to
the market. Pfizer Inc., Johnson & Johnson Pvt. Ltd., Array BioPharma,
AstraZeneca, GlaxoSmithKline Plc., and Sanofi are some of the major
participants.
Comments
Post a Comment